Comparison of the efficacy and tolerability of chondroitin plus glucosamine and D-002 (beeswax alcohols) in subjects with osteoarthritis symptoms

<p<<strong<Background</strong<<strong</AIMS:</strong< Osteoarthritis (OA), the commonest joint disorder, is a leading cause of disability. Symptomatic slow-acting drugs for OA (SYSADOA), particularly glucosamine plus chondroitin sulphate (GS/CS), are effective for sympt...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Sarahi Mendoza [verfasserIn] Roberto Puente [verfasserIn] José Illnait [verfasserIn] Rosa Mas [verfasserIn] Ernesto López [verfasserIn] Daisy Carbajal [verfasserIn] Lilia Fernández [verfasserIn] Julio Fernández [verfasserIn] Meilis Mesa [verfasserIn] Pablo Reyes [verfasserIn] Dalmer Ruiz [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch ; Spanisch ; Portugiesisch

Erschienen:	2017

Schlagwörter:	D-002, beeswax alcohols, chondroitin sulphate, glucosamine, osteoarthritis, WOMAC score, VAS score

Übergeordnetes Werk:	In: Revista de la Facultad de Ciencias Médicas de Córdoba - Universidad Nacional de Córdoba, 2019, 74(2017), 2, Seite 107-118
Übergeordnetes Werk:	volume:74 ; year:2017 ; number:2 ; pages:107-118

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc Journal toc

DOI / URN:	10.31053/1853.0605.v74.n2.14479

Katalog-ID:	DOAJ053607759

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ053607759
003	DE-627
005	20230308174724.0
007	cr uuu---uuuuu
008	230227s2017 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.31053/1853.0605.v74.n2.14479 \|2 doi
035			\|a (DE-627)DOAJ053607759
035			\|a (DE-599)DOAJ9f4af7772b29417499bba08598098ab2
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng \|a spa \|a por
050		0	\|a R5-920
100	0		\|a Sarahi Mendoza \|e verfasserin \|4 aut
245	1	0	\|a Comparison of the efficacy and tolerability of chondroitin plus glucosamine and D-002 (beeswax alcohols) in subjects with osteoarthritis symptoms
264		1	\|c 2017
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a <p<<strong<Background</strong<<strong</AIMS:</strong< Osteoarthritis (OA), the commonest joint disorder, is a leading cause of disability. Symptomatic slow-acting drugs for OA (SYSADOA), particularly glucosamine plus chondroitin sulphate (GS/CS), are effective for symptom relief, protect joint cartilage and delay OA progression, with a good safety profile.<strong< </strong<D-002, a mixture of beeswax alcohols that inhibits both cyclooxygenase and 5-lipoxygenase activities, has been effective in experimental and clinical OA studies, showing also a chondroprotective effect.</p<<p<<strong<OBJECTIVES:</strong< To compare the effects of D-002 and GS/SC administered for 12 weeks on OA symptoms.</p<<p<<strong<METHODS:</strong< Participants were randomized to GS/CS (375/300 mg) or 50?mg D-002 once daily for 12 weeks. Symptoms were assessed by the Western Ontario and McMaster Individual Osteoarthritis Index (WOMAC) and the visual analogy scale (VAS) scores. The primary outcome was the reduction of the total WOMAC score. Secondary outcomes included WOMAC pain, stiffness and function scores, VAS score and rescue medication consumption.</p<<p<<strong<RESULTS:</strong< Of 60 randomized patients, 59 completed the study. D-002 and GS/SC reduced significantly total WOMAC score (72.1% and 78.5%, respectively), and pain, joint stiffness and physical function scores versus baseline. VAS scores decreased significantly with D-002 (76.6%) and GS/SC (76.8%). The reductions, significant from the second week, were enhanced over the trial. Rescue medications were consumed by 3/30 D-002 and 4/30 GS/SC patients. No differences between groups were found. Treatments were well tolerated.</p<<h4<CONCLUSIONS: D-002 (50 mg/day) administered for 12 weeks was safe and comparable to GS/SC for alleviating OA symptoms (pain, stiffness, and functional limitation) (RPCEC00000180).</h4<
650		4	\|a D-002, beeswax alcohols, chondroitin sulphate, glucosamine, osteoarthritis, WOMAC score, VAS score
653		0	\|a Medicine
653		0	\|a R
653		0	\|a Medicine (General)
700	0		\|a Roberto Puente \|e verfasserin \|4 aut
700	0		\|a José Illnait \|e verfasserin \|4 aut
700	0		\|a Rosa Mas \|e verfasserin \|4 aut
700	0		\|a Ernesto López \|e verfasserin \|4 aut
700	0		\|a Daisy Carbajal \|e verfasserin \|4 aut
700	0		\|a Lilia Fernández \|e verfasserin \|4 aut
700	0		\|a Julio Fernández \|e verfasserin \|4 aut
700	0		\|a Meilis Mesa \|e verfasserin \|4 aut
700	0		\|a Pablo Reyes \|e verfasserin \|4 aut
700	0		\|a Dalmer Ruiz \|e verfasserin \|4 aut
773	0	8	\|i In \|t Revista de la Facultad de Ciencias Médicas de Córdoba \|d Universidad Nacional de Córdoba, 2019 \|g 74(2017), 2, Seite 107-118 \|w (DE-627)688608272 \|w (DE-600)2654370-9 \|x 18530605 \|7 nnns
773	1	8	\|g volume:74 \|g year:2017 \|g number:2 \|g pages:107-118
856	4	0	\|u https://doi.org/10.31053/1853.0605.v74.n2.14479 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/9f4af7772b29417499bba08598098ab2 \|z kostenfrei
856	4	0	\|u https://revistas.unc.edu.ar/index.php/med/article/view/14479 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/0014-6722 \|y Journal toc \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/1853-0605 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 74 \|j 2017 \|e 2 \|h 107-118

Indexfelder

author_variant	s m sm r p rp j i ji r m rm e l el d c dc l f lf j f jf m m mm p r pr d r dr
matchkey_str	article:18530605:2017----::oprsnfhefccadoeaiiyfhnriipuguoaiend0bewxloosnu
hierarchy_sort_str	2017
callnumber-subject-code	R
publishDate	2017
allfields	10.31053/1853.0605.v74.n2.14479 doi (DE-627)DOAJ053607759 (DE-599)DOAJ9f4af7772b29417499bba08598098ab2 DE-627 ger DE-627 rakwb eng spa por R5-920 Sarahi Mendoza verfasserin aut Comparison of the efficacy and tolerability of chondroitin plus glucosamine and D-002 (beeswax alcohols) in subjects with osteoarthritis symptoms 2017 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <p<<strong<Background</strong<<strong</AIMS:</strong< Osteoarthritis (OA), the commonest joint disorder, is a leading cause of disability. Symptomatic slow-acting drugs for OA (SYSADOA), particularly glucosamine plus chondroitin sulphate (GS/CS), are effective for symptom relief, protect joint cartilage and delay OA progression, with a good safety profile.<strong< </strong<D-002, a mixture of beeswax alcohols that inhibits both cyclooxygenase and 5-lipoxygenase activities, has been effective in experimental and clinical OA studies, showing also a chondroprotective effect.</p<<p<<strong<OBJECTIVES:</strong< To compare the effects of D-002 and GS/SC administered for 12 weeks on OA symptoms.</p<<p<<strong<METHODS:</strong< Participants were randomized to GS/CS (375/300 mg) or 50?mg D-002 once daily for 12 weeks. Symptoms were assessed by the Western Ontario and McMaster Individual Osteoarthritis Index (WOMAC) and the visual analogy scale (VAS) scores. The primary outcome was the reduction of the total WOMAC score. Secondary outcomes included WOMAC pain, stiffness and function scores, VAS score and rescue medication consumption.</p<<p<<strong<RESULTS:</strong< Of 60 randomized patients, 59 completed the study. D-002 and GS/SC reduced significantly total WOMAC score (72.1% and 78.5%, respectively), and pain, joint stiffness and physical function scores versus baseline. VAS scores decreased significantly with D-002 (76.6%) and GS/SC (76.8%). The reductions, significant from the second week, were enhanced over the trial. Rescue medications were consumed by 3/30 D-002 and 4/30 GS/SC patients. No differences between groups were found. Treatments were well tolerated.</p<<h4<CONCLUSIONS: D-002 (50 mg/day) administered for 12 weeks was safe and comparable to GS/SC for alleviating OA symptoms (pain, stiffness, and functional limitation) (RPCEC00000180).</h4< D-002, beeswax alcohols, chondroitin sulphate, glucosamine, osteoarthritis, WOMAC score, VAS score Medicine R Medicine (General) Roberto Puente verfasserin aut José Illnait verfasserin aut Rosa Mas verfasserin aut Ernesto López verfasserin aut Daisy Carbajal verfasserin aut Lilia Fernández verfasserin aut Julio Fernández verfasserin aut Meilis Mesa verfasserin aut Pablo Reyes verfasserin aut Dalmer Ruiz verfasserin aut In Revista de la Facultad de Ciencias Médicas de Córdoba Universidad Nacional de Córdoba, 2019 74(2017), 2, Seite 107-118 (DE-627)688608272 (DE-600)2654370-9 18530605 nnns volume:74 year:2017 number:2 pages:107-118 https://doi.org/10.31053/1853.0605.v74.n2.14479 kostenfrei https://doaj.org/article/9f4af7772b29417499bba08598098ab2 kostenfrei https://revistas.unc.edu.ar/index.php/med/article/view/14479 kostenfrei https://doaj.org/toc/0014-6722 Journal toc kostenfrei https://doaj.org/toc/1853-0605 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 74 2017 2 107-118
spelling	10.31053/1853.0605.v74.n2.14479 doi (DE-627)DOAJ053607759 (DE-599)DOAJ9f4af7772b29417499bba08598098ab2 DE-627 ger DE-627 rakwb eng spa por R5-920 Sarahi Mendoza verfasserin aut Comparison of the efficacy and tolerability of chondroitin plus glucosamine and D-002 (beeswax alcohols) in subjects with osteoarthritis symptoms 2017 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <p<<strong<Background</strong<<strong</AIMS:</strong< Osteoarthritis (OA), the commonest joint disorder, is a leading cause of disability. Symptomatic slow-acting drugs for OA (SYSADOA), particularly glucosamine plus chondroitin sulphate (GS/CS), are effective for symptom relief, protect joint cartilage and delay OA progression, with a good safety profile.<strong< </strong<D-002, a mixture of beeswax alcohols that inhibits both cyclooxygenase and 5-lipoxygenase activities, has been effective in experimental and clinical OA studies, showing also a chondroprotective effect.</p<<p<<strong<OBJECTIVES:</strong< To compare the effects of D-002 and GS/SC administered for 12 weeks on OA symptoms.</p<<p<<strong<METHODS:</strong< Participants were randomized to GS/CS (375/300 mg) or 50?mg D-002 once daily for 12 weeks. Symptoms were assessed by the Western Ontario and McMaster Individual Osteoarthritis Index (WOMAC) and the visual analogy scale (VAS) scores. The primary outcome was the reduction of the total WOMAC score. Secondary outcomes included WOMAC pain, stiffness and function scores, VAS score and rescue medication consumption.</p<<p<<strong<RESULTS:</strong< Of 60 randomized patients, 59 completed the study. D-002 and GS/SC reduced significantly total WOMAC score (72.1% and 78.5%, respectively), and pain, joint stiffness and physical function scores versus baseline. VAS scores decreased significantly with D-002 (76.6%) and GS/SC (76.8%). The reductions, significant from the second week, were enhanced over the trial. Rescue medications were consumed by 3/30 D-002 and 4/30 GS/SC patients. No differences between groups were found. Treatments were well tolerated.</p<<h4<CONCLUSIONS: D-002 (50 mg/day) administered for 12 weeks was safe and comparable to GS/SC for alleviating OA symptoms (pain, stiffness, and functional limitation) (RPCEC00000180).</h4< D-002, beeswax alcohols, chondroitin sulphate, glucosamine, osteoarthritis, WOMAC score, VAS score Medicine R Medicine (General) Roberto Puente verfasserin aut José Illnait verfasserin aut Rosa Mas verfasserin aut Ernesto López verfasserin aut Daisy Carbajal verfasserin aut Lilia Fernández verfasserin aut Julio Fernández verfasserin aut Meilis Mesa verfasserin aut Pablo Reyes verfasserin aut Dalmer Ruiz verfasserin aut In Revista de la Facultad de Ciencias Médicas de Córdoba Universidad Nacional de Córdoba, 2019 74(2017), 2, Seite 107-118 (DE-627)688608272 (DE-600)2654370-9 18530605 nnns volume:74 year:2017 number:2 pages:107-118 https://doi.org/10.31053/1853.0605.v74.n2.14479 kostenfrei https://doaj.org/article/9f4af7772b29417499bba08598098ab2 kostenfrei https://revistas.unc.edu.ar/index.php/med/article/view/14479 kostenfrei https://doaj.org/toc/0014-6722 Journal toc kostenfrei https://doaj.org/toc/1853-0605 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 74 2017 2 107-118
allfields_unstemmed	10.31053/1853.0605.v74.n2.14479 doi (DE-627)DOAJ053607759 (DE-599)DOAJ9f4af7772b29417499bba08598098ab2 DE-627 ger DE-627 rakwb eng spa por R5-920 Sarahi Mendoza verfasserin aut Comparison of the efficacy and tolerability of chondroitin plus glucosamine and D-002 (beeswax alcohols) in subjects with osteoarthritis symptoms 2017 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <p<<strong<Background</strong<<strong</AIMS:</strong< Osteoarthritis (OA), the commonest joint disorder, is a leading cause of disability. Symptomatic slow-acting drugs for OA (SYSADOA), particularly glucosamine plus chondroitin sulphate (GS/CS), are effective for symptom relief, protect joint cartilage and delay OA progression, with a good safety profile.<strong< </strong<D-002, a mixture of beeswax alcohols that inhibits both cyclooxygenase and 5-lipoxygenase activities, has been effective in experimental and clinical OA studies, showing also a chondroprotective effect.</p<<p<<strong<OBJECTIVES:</strong< To compare the effects of D-002 and GS/SC administered for 12 weeks on OA symptoms.</p<<p<<strong<METHODS:</strong< Participants were randomized to GS/CS (375/300 mg) or 50?mg D-002 once daily for 12 weeks. Symptoms were assessed by the Western Ontario and McMaster Individual Osteoarthritis Index (WOMAC) and the visual analogy scale (VAS) scores. The primary outcome was the reduction of the total WOMAC score. Secondary outcomes included WOMAC pain, stiffness and function scores, VAS score and rescue medication consumption.</p<<p<<strong<RESULTS:</strong< Of 60 randomized patients, 59 completed the study. D-002 and GS/SC reduced significantly total WOMAC score (72.1% and 78.5%, respectively), and pain, joint stiffness and physical function scores versus baseline. VAS scores decreased significantly with D-002 (76.6%) and GS/SC (76.8%). The reductions, significant from the second week, were enhanced over the trial. Rescue medications were consumed by 3/30 D-002 and 4/30 GS/SC patients. No differences between groups were found. Treatments were well tolerated.</p<<h4<CONCLUSIONS: D-002 (50 mg/day) administered for 12 weeks was safe and comparable to GS/SC for alleviating OA symptoms (pain, stiffness, and functional limitation) (RPCEC00000180).</h4< D-002, beeswax alcohols, chondroitin sulphate, glucosamine, osteoarthritis, WOMAC score, VAS score Medicine R Medicine (General) Roberto Puente verfasserin aut José Illnait verfasserin aut Rosa Mas verfasserin aut Ernesto López verfasserin aut Daisy Carbajal verfasserin aut Lilia Fernández verfasserin aut Julio Fernández verfasserin aut Meilis Mesa verfasserin aut Pablo Reyes verfasserin aut Dalmer Ruiz verfasserin aut In Revista de la Facultad de Ciencias Médicas de Córdoba Universidad Nacional de Córdoba, 2019 74(2017), 2, Seite 107-118 (DE-627)688608272 (DE-600)2654370-9 18530605 nnns volume:74 year:2017 number:2 pages:107-118 https://doi.org/10.31053/1853.0605.v74.n2.14479 kostenfrei https://doaj.org/article/9f4af7772b29417499bba08598098ab2 kostenfrei https://revistas.unc.edu.ar/index.php/med/article/view/14479 kostenfrei https://doaj.org/toc/0014-6722 Journal toc kostenfrei https://doaj.org/toc/1853-0605 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 74 2017 2 107-118
allfieldsGer	10.31053/1853.0605.v74.n2.14479 doi (DE-627)DOAJ053607759 (DE-599)DOAJ9f4af7772b29417499bba08598098ab2 DE-627 ger DE-627 rakwb eng spa por R5-920 Sarahi Mendoza verfasserin aut Comparison of the efficacy and tolerability of chondroitin plus glucosamine and D-002 (beeswax alcohols) in subjects with osteoarthritis symptoms 2017 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <p<<strong<Background</strong<<strong</AIMS:</strong< Osteoarthritis (OA), the commonest joint disorder, is a leading cause of disability. Symptomatic slow-acting drugs for OA (SYSADOA), particularly glucosamine plus chondroitin sulphate (GS/CS), are effective for symptom relief, protect joint cartilage and delay OA progression, with a good safety profile.<strong< </strong<D-002, a mixture of beeswax alcohols that inhibits both cyclooxygenase and 5-lipoxygenase activities, has been effective in experimental and clinical OA studies, showing also a chondroprotective effect.</p<<p<<strong<OBJECTIVES:</strong< To compare the effects of D-002 and GS/SC administered for 12 weeks on OA symptoms.</p<<p<<strong<METHODS:</strong< Participants were randomized to GS/CS (375/300 mg) or 50?mg D-002 once daily for 12 weeks. Symptoms were assessed by the Western Ontario and McMaster Individual Osteoarthritis Index (WOMAC) and the visual analogy scale (VAS) scores. The primary outcome was the reduction of the total WOMAC score. Secondary outcomes included WOMAC pain, stiffness and function scores, VAS score and rescue medication consumption.</p<<p<<strong<RESULTS:</strong< Of 60 randomized patients, 59 completed the study. D-002 and GS/SC reduced significantly total WOMAC score (72.1% and 78.5%, respectively), and pain, joint stiffness and physical function scores versus baseline. VAS scores decreased significantly with D-002 (76.6%) and GS/SC (76.8%). The reductions, significant from the second week, were enhanced over the trial. Rescue medications were consumed by 3/30 D-002 and 4/30 GS/SC patients. No differences between groups were found. Treatments were well tolerated.</p<<h4<CONCLUSIONS: D-002 (50 mg/day) administered for 12 weeks was safe and comparable to GS/SC for alleviating OA symptoms (pain, stiffness, and functional limitation) (RPCEC00000180).</h4< D-002, beeswax alcohols, chondroitin sulphate, glucosamine, osteoarthritis, WOMAC score, VAS score Medicine R Medicine (General) Roberto Puente verfasserin aut José Illnait verfasserin aut Rosa Mas verfasserin aut Ernesto López verfasserin aut Daisy Carbajal verfasserin aut Lilia Fernández verfasserin aut Julio Fernández verfasserin aut Meilis Mesa verfasserin aut Pablo Reyes verfasserin aut Dalmer Ruiz verfasserin aut In Revista de la Facultad de Ciencias Médicas de Córdoba Universidad Nacional de Córdoba, 2019 74(2017), 2, Seite 107-118 (DE-627)688608272 (DE-600)2654370-9 18530605 nnns volume:74 year:2017 number:2 pages:107-118 https://doi.org/10.31053/1853.0605.v74.n2.14479 kostenfrei https://doaj.org/article/9f4af7772b29417499bba08598098ab2 kostenfrei https://revistas.unc.edu.ar/index.php/med/article/view/14479 kostenfrei https://doaj.org/toc/0014-6722 Journal toc kostenfrei https://doaj.org/toc/1853-0605 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 74 2017 2 107-118
allfieldsSound	10.31053/1853.0605.v74.n2.14479 doi (DE-627)DOAJ053607759 (DE-599)DOAJ9f4af7772b29417499bba08598098ab2 DE-627 ger DE-627 rakwb eng spa por R5-920 Sarahi Mendoza verfasserin aut Comparison of the efficacy and tolerability of chondroitin plus glucosamine and D-002 (beeswax alcohols) in subjects with osteoarthritis symptoms 2017 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <p<<strong<Background</strong<<strong</AIMS:</strong< Osteoarthritis (OA), the commonest joint disorder, is a leading cause of disability. Symptomatic slow-acting drugs for OA (SYSADOA), particularly glucosamine plus chondroitin sulphate (GS/CS), are effective for symptom relief, protect joint cartilage and delay OA progression, with a good safety profile.<strong< </strong<D-002, a mixture of beeswax alcohols that inhibits both cyclooxygenase and 5-lipoxygenase activities, has been effective in experimental and clinical OA studies, showing also a chondroprotective effect.</p<<p<<strong<OBJECTIVES:</strong< To compare the effects of D-002 and GS/SC administered for 12 weeks on OA symptoms.</p<<p<<strong<METHODS:</strong< Participants were randomized to GS/CS (375/300 mg) or 50?mg D-002 once daily for 12 weeks. Symptoms were assessed by the Western Ontario and McMaster Individual Osteoarthritis Index (WOMAC) and the visual analogy scale (VAS) scores. The primary outcome was the reduction of the total WOMAC score. Secondary outcomes included WOMAC pain, stiffness and function scores, VAS score and rescue medication consumption.</p<<p<<strong<RESULTS:</strong< Of 60 randomized patients, 59 completed the study. D-002 and GS/SC reduced significantly total WOMAC score (72.1% and 78.5%, respectively), and pain, joint stiffness and physical function scores versus baseline. VAS scores decreased significantly with D-002 (76.6%) and GS/SC (76.8%). The reductions, significant from the second week, were enhanced over the trial. Rescue medications were consumed by 3/30 D-002 and 4/30 GS/SC patients. No differences between groups were found. Treatments were well tolerated.</p<<h4<CONCLUSIONS: D-002 (50 mg/day) administered for 12 weeks was safe and comparable to GS/SC for alleviating OA symptoms (pain, stiffness, and functional limitation) (RPCEC00000180).</h4< D-002, beeswax alcohols, chondroitin sulphate, glucosamine, osteoarthritis, WOMAC score, VAS score Medicine R Medicine (General) Roberto Puente verfasserin aut José Illnait verfasserin aut Rosa Mas verfasserin aut Ernesto López verfasserin aut Daisy Carbajal verfasserin aut Lilia Fernández verfasserin aut Julio Fernández verfasserin aut Meilis Mesa verfasserin aut Pablo Reyes verfasserin aut Dalmer Ruiz verfasserin aut In Revista de la Facultad de Ciencias Médicas de Córdoba Universidad Nacional de Córdoba, 2019 74(2017), 2, Seite 107-118 (DE-627)688608272 (DE-600)2654370-9 18530605 nnns volume:74 year:2017 number:2 pages:107-118 https://doi.org/10.31053/1853.0605.v74.n2.14479 kostenfrei https://doaj.org/article/9f4af7772b29417499bba08598098ab2 kostenfrei https://revistas.unc.edu.ar/index.php/med/article/view/14479 kostenfrei https://doaj.org/toc/0014-6722 Journal toc kostenfrei https://doaj.org/toc/1853-0605 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 74 2017 2 107-118
language	English Spanish Portuguese
source	In Revista de la Facultad de Ciencias Médicas de Córdoba 74(2017), 2, Seite 107-118 volume:74 year:2017 number:2 pages:107-118
sourceStr	In Revista de la Facultad de Ciencias Médicas de Córdoba 74(2017), 2, Seite 107-118 volume:74 year:2017 number:2 pages:107-118
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	D-002, beeswax alcohols, chondroitin sulphate, glucosamine, osteoarthritis, WOMAC score, VAS score Medicine R Medicine (General)
isfreeaccess_bool	true
container_title	Revista de la Facultad de Ciencias Médicas de Córdoba
authorswithroles_txt_mv	Sarahi Mendoza @@aut@@ Roberto Puente @@aut@@ José Illnait @@aut@@ Rosa Mas @@aut@@ Ernesto López @@aut@@ Daisy Carbajal @@aut@@ Lilia Fernández @@aut@@ Julio Fernández @@aut@@ Meilis Mesa @@aut@@ Pablo Reyes @@aut@@ Dalmer Ruiz @@aut@@
publishDateDaySort_date	2017-01-01T00:00:00Z
hierarchy_top_id	688608272
id	DOAJ053607759
language_de	englisch spanisch portugiesisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ053607759</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230308174724.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2017 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.31053/1853.0605.v74.n2.14479</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ053607759</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ9f4af7772b29417499bba08598098ab2</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield><subfield code="a">spa</subfield><subfield code="a">por</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">R5-920</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Sarahi Mendoza</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Comparison of the efficacy and tolerability of chondroitin plus glucosamine and D-002 (beeswax alcohols) in subjects with osteoarthritis symptoms</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a"><p<<strong<Background</strong<<strong</AIMS:</strong< Osteoarthritis (OA), the commonest joint disorder, is a leading cause of disability. Symptomatic slow-acting drugs for OA (SYSADOA), particularly glucosamine plus chondroitin sulphate (GS/CS), are effective for symptom relief, protect joint cartilage and delay OA progression, with a good safety profile.<strong< </strong<D-002, a mixture of beeswax alcohols that inhibits both cyclooxygenase and 5-lipoxygenase activities, has been effective in experimental and clinical OA studies, showing also a chondroprotective effect.</p<<p<<strong<OBJECTIVES:</strong< To compare the effects of D-002 and GS/SC administered for 12 weeks on OA symptoms.</p<<p<<strong<METHODS:</strong< Participants were randomized to GS/CS (375/300 mg) or 50?mg D-002 once daily for 12 weeks. Symptoms were assessed by the Western Ontario and McMaster Individual Osteoarthritis Index (WOMAC) and the visual analogy scale (VAS) scores. The primary outcome was the reduction of the total WOMAC score. Secondary outcomes included WOMAC pain, stiffness and function scores, VAS score and rescue medication consumption.</p<<p<<strong<RESULTS:</strong< Of 60 randomized patients, 59 completed the study. D-002 and GS/SC reduced significantly total WOMAC score (72.1% and 78.5%, respectively), and pain, joint stiffness and physical function scores versus baseline. VAS scores decreased significantly with D-002 (76.6%) and GS/SC (76.8%). The reductions, significant from the second week, were enhanced over the trial. Rescue medications were consumed by 3/30 D-002 and 4/30 GS/SC patients. No differences between groups were found. Treatments were well tolerated.</p<<h4<CONCLUSIONS: D-002 (50 mg/day) administered for 12 weeks was safe and comparable to GS/SC for alleviating OA symptoms (pain, stiffness, and functional limitation) (RPCEC00000180).</h4<</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">D-002, beeswax alcohols, chondroitin sulphate, glucosamine, osteoarthritis, WOMAC score, VAS score</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine (General)</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Roberto Puente</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">José Illnait</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Rosa Mas</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ernesto López</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Daisy Carbajal</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Lilia Fernández</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Julio Fernández</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Meilis Mesa</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Pablo Reyes</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Dalmer Ruiz</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Revista de la Facultad de Ciencias Médicas de Córdoba</subfield><subfield code="d">Universidad Nacional de Córdoba, 2019</subfield><subfield code="g">74(2017), 2, Seite 107-118</subfield><subfield code="w">(DE-627)688608272</subfield><subfield code="w">(DE-600)2654370-9</subfield><subfield code="x">18530605</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:74</subfield><subfield code="g">year:2017</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:107-118</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.31053/1853.0605.v74.n2.14479</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/9f4af7772b29417499bba08598098ab2</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://revistas.unc.edu.ar/index.php/med/article/view/14479</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/0014-6722</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1853-0605</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">74</subfield><subfield code="j">2017</subfield><subfield code="e">2</subfield><subfield code="h">107-118</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	Sarahi Mendoza
spellingShingle	Sarahi Mendoza misc R5-920 misc D-002, beeswax alcohols, chondroitin sulphate, glucosamine, osteoarthritis, WOMAC score, VAS score misc Medicine misc R misc Medicine (General) Comparison of the efficacy and tolerability of chondroitin plus glucosamine and D-002 (beeswax alcohols) in subjects with osteoarthritis symptoms
authorStr	Sarahi Mendoza
ppnlink_with_tag_str_mv	@@773@@(DE-627)688608272
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut aut aut aut aut aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	R5-920
illustrated	Not Illustrated
issn	18530605
topic_title	R5-920 Comparison of the efficacy and tolerability of chondroitin plus glucosamine and D-002 (beeswax alcohols) in subjects with osteoarthritis symptoms D-002, beeswax alcohols, chondroitin sulphate, glucosamine, osteoarthritis, WOMAC score, VAS score
topic	misc R5-920 misc D-002, beeswax alcohols, chondroitin sulphate, glucosamine, osteoarthritis, WOMAC score, VAS score misc Medicine misc R misc Medicine (General)
topic_unstemmed	misc R5-920 misc D-002, beeswax alcohols, chondroitin sulphate, glucosamine, osteoarthritis, WOMAC score, VAS score misc Medicine misc R misc Medicine (General)
topic_browse	misc R5-920 misc D-002, beeswax alcohols, chondroitin sulphate, glucosamine, osteoarthritis, WOMAC score, VAS score misc Medicine misc R misc Medicine (General)
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Revista de la Facultad de Ciencias Médicas de Córdoba
hierarchy_parent_id	688608272
hierarchy_top_title	Revista de la Facultad de Ciencias Médicas de Córdoba
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)688608272 (DE-600)2654370-9
title	Comparison of the efficacy and tolerability of chondroitin plus glucosamine and D-002 (beeswax alcohols) in subjects with osteoarthritis symptoms
ctrlnum	(DE-627)DOAJ053607759 (DE-599)DOAJ9f4af7772b29417499bba08598098ab2
title_full	Comparison of the efficacy and tolerability of chondroitin plus glucosamine and D-002 (beeswax alcohols) in subjects with osteoarthritis symptoms
author_sort	Sarahi Mendoza
journal	Revista de la Facultad de Ciencias Médicas de Córdoba
journalStr	Revista de la Facultad de Ciencias Médicas de Córdoba
callnumber-first-code	R
lang_code	eng spa por
isOA_bool	true
recordtype	marc
publishDateSort	2017
contenttype_str_mv	txt
container_start_page	107
author_browse	Sarahi Mendoza Roberto Puente José Illnait Rosa Mas Ernesto López Daisy Carbajal Lilia Fernández Julio Fernández Meilis Mesa Pablo Reyes Dalmer Ruiz
container_volume	74
class	R5-920
format_se	Elektronische Aufsätze
author-letter	Sarahi Mendoza
doi_str_mv	10.31053/1853.0605.v74.n2.14479
author2-role	verfasserin
title_sort	comparison of the efficacy and tolerability of chondroitin plus glucosamine and d-002 (beeswax alcohols) in subjects with osteoarthritis symptoms
callnumber	R5-920
title_auth	Comparison of the efficacy and tolerability of chondroitin plus glucosamine and D-002 (beeswax alcohols) in subjects with osteoarthritis symptoms
abstract	<p<<strong<Background</strong<<strong</AIMS:</strong< Osteoarthritis (OA), the commonest joint disorder, is a leading cause of disability. Symptomatic slow-acting drugs for OA (SYSADOA), particularly glucosamine plus chondroitin sulphate (GS/CS), are effective for symptom relief, protect joint cartilage and delay OA progression, with a good safety profile.<strong< </strong<D-002, a mixture of beeswax alcohols that inhibits both cyclooxygenase and 5-lipoxygenase activities, has been effective in experimental and clinical OA studies, showing also a chondroprotective effect.</p<<p<<strong<OBJECTIVES:</strong< To compare the effects of D-002 and GS/SC administered for 12 weeks on OA symptoms.</p<<p<<strong<METHODS:</strong< Participants were randomized to GS/CS (375/300 mg) or 50?mg D-002 once daily for 12 weeks. Symptoms were assessed by the Western Ontario and McMaster Individual Osteoarthritis Index (WOMAC) and the visual analogy scale (VAS) scores. The primary outcome was the reduction of the total WOMAC score. Secondary outcomes included WOMAC pain, stiffness and function scores, VAS score and rescue medication consumption.</p<<p<<strong<RESULTS:</strong< Of 60 randomized patients, 59 completed the study. D-002 and GS/SC reduced significantly total WOMAC score (72.1% and 78.5%, respectively), and pain, joint stiffness and physical function scores versus baseline. VAS scores decreased significantly with D-002 (76.6%) and GS/SC (76.8%). The reductions, significant from the second week, were enhanced over the trial. Rescue medications were consumed by 3/30 D-002 and 4/30 GS/SC patients. No differences between groups were found. Treatments were well tolerated.</p<<h4<CONCLUSIONS: D-002 (50 mg/day) administered for 12 weeks was safe and comparable to GS/SC for alleviating OA symptoms (pain, stiffness, and functional limitation) (RPCEC00000180).</h4<
abstractGer	<p<<strong<Background</strong<<strong</AIMS:</strong< Osteoarthritis (OA), the commonest joint disorder, is a leading cause of disability. Symptomatic slow-acting drugs for OA (SYSADOA), particularly glucosamine plus chondroitin sulphate (GS/CS), are effective for symptom relief, protect joint cartilage and delay OA progression, with a good safety profile.<strong< </strong<D-002, a mixture of beeswax alcohols that inhibits both cyclooxygenase and 5-lipoxygenase activities, has been effective in experimental and clinical OA studies, showing also a chondroprotective effect.</p<<p<<strong<OBJECTIVES:</strong< To compare the effects of D-002 and GS/SC administered for 12 weeks on OA symptoms.</p<<p<<strong<METHODS:</strong< Participants were randomized to GS/CS (375/300 mg) or 50?mg D-002 once daily for 12 weeks. Symptoms were assessed by the Western Ontario and McMaster Individual Osteoarthritis Index (WOMAC) and the visual analogy scale (VAS) scores. The primary outcome was the reduction of the total WOMAC score. Secondary outcomes included WOMAC pain, stiffness and function scores, VAS score and rescue medication consumption.</p<<p<<strong<RESULTS:</strong< Of 60 randomized patients, 59 completed the study. D-002 and GS/SC reduced significantly total WOMAC score (72.1% and 78.5%, respectively), and pain, joint stiffness and physical function scores versus baseline. VAS scores decreased significantly with D-002 (76.6%) and GS/SC (76.8%). The reductions, significant from the second week, were enhanced over the trial. Rescue medications were consumed by 3/30 D-002 and 4/30 GS/SC patients. No differences between groups were found. Treatments were well tolerated.</p<<h4<CONCLUSIONS: D-002 (50 mg/day) administered for 12 weeks was safe and comparable to GS/SC for alleviating OA symptoms (pain, stiffness, and functional limitation) (RPCEC00000180).</h4<
abstract_unstemmed	<p<<strong<Background</strong<<strong</AIMS:</strong< Osteoarthritis (OA), the commonest joint disorder, is a leading cause of disability. Symptomatic slow-acting drugs for OA (SYSADOA), particularly glucosamine plus chondroitin sulphate (GS/CS), are effective for symptom relief, protect joint cartilage and delay OA progression, with a good safety profile.<strong< </strong<D-002, a mixture of beeswax alcohols that inhibits both cyclooxygenase and 5-lipoxygenase activities, has been effective in experimental and clinical OA studies, showing also a chondroprotective effect.</p<<p<<strong<OBJECTIVES:</strong< To compare the effects of D-002 and GS/SC administered for 12 weeks on OA symptoms.</p<<p<<strong<METHODS:</strong< Participants were randomized to GS/CS (375/300 mg) or 50?mg D-002 once daily for 12 weeks. Symptoms were assessed by the Western Ontario and McMaster Individual Osteoarthritis Index (WOMAC) and the visual analogy scale (VAS) scores. The primary outcome was the reduction of the total WOMAC score. Secondary outcomes included WOMAC pain, stiffness and function scores, VAS score and rescue medication consumption.</p<<p<<strong<RESULTS:</strong< Of 60 randomized patients, 59 completed the study. D-002 and GS/SC reduced significantly total WOMAC score (72.1% and 78.5%, respectively), and pain, joint stiffness and physical function scores versus baseline. VAS scores decreased significantly with D-002 (76.6%) and GS/SC (76.8%). The reductions, significant from the second week, were enhanced over the trial. Rescue medications were consumed by 3/30 D-002 and 4/30 GS/SC patients. No differences between groups were found. Treatments were well tolerated.</p<<h4<CONCLUSIONS: D-002 (50 mg/day) administered for 12 weeks was safe and comparable to GS/SC for alleviating OA symptoms (pain, stiffness, and functional limitation) (RPCEC00000180).</h4<
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	2
title_short	Comparison of the efficacy and tolerability of chondroitin plus glucosamine and D-002 (beeswax alcohols) in subjects with osteoarthritis symptoms
url	https://doi.org/10.31053/1853.0605.v74.n2.14479 https://doaj.org/article/9f4af7772b29417499bba08598098ab2 https://revistas.unc.edu.ar/index.php/med/article/view/14479 https://doaj.org/toc/0014-6722 https://doaj.org/toc/1853-0605
remote_bool	true
author2	Roberto Puente José Illnait Rosa Mas Ernesto López Daisy Carbajal Lilia Fernández Julio Fernández Meilis Mesa Pablo Reyes Dalmer Ruiz
author2Str	Roberto Puente José Illnait Rosa Mas Ernesto López Daisy Carbajal Lilia Fernández Julio Fernández Meilis Mesa Pablo Reyes Dalmer Ruiz
ppnlink	688608272
callnumber-subject	R - General Medicine
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.31053/1853.0605.v74.n2.14479
callnumber-a	R5-920
up_date	2024-07-03T18:36:03.186Z
_version_	1803584026117668864
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ053607759</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230308174724.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2017 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.31053/1853.0605.v74.n2.14479</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ053607759</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ9f4af7772b29417499bba08598098ab2</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield><subfield code="a">spa</subfield><subfield code="a">por</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">R5-920</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Sarahi Mendoza</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Comparison of the efficacy and tolerability of chondroitin plus glucosamine and D-002 (beeswax alcohols) in subjects with osteoarthritis symptoms</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a"><p<<strong<Background</strong<<strong</AIMS:</strong< Osteoarthritis (OA), the commonest joint disorder, is a leading cause of disability. Symptomatic slow-acting drugs for OA (SYSADOA), particularly glucosamine plus chondroitin sulphate (GS/CS), are effective for symptom relief, protect joint cartilage and delay OA progression, with a good safety profile.<strong< </strong<D-002, a mixture of beeswax alcohols that inhibits both cyclooxygenase and 5-lipoxygenase activities, has been effective in experimental and clinical OA studies, showing also a chondroprotective effect.</p<<p<<strong<OBJECTIVES:</strong< To compare the effects of D-002 and GS/SC administered for 12 weeks on OA symptoms.</p<<p<<strong<METHODS:</strong< Participants were randomized to GS/CS (375/300 mg) or 50?mg D-002 once daily for 12 weeks. Symptoms were assessed by the Western Ontario and McMaster Individual Osteoarthritis Index (WOMAC) and the visual analogy scale (VAS) scores. The primary outcome was the reduction of the total WOMAC score. Secondary outcomes included WOMAC pain, stiffness and function scores, VAS score and rescue medication consumption.</p<<p<<strong<RESULTS:</strong< Of 60 randomized patients, 59 completed the study. D-002 and GS/SC reduced significantly total WOMAC score (72.1% and 78.5%, respectively), and pain, joint stiffness and physical function scores versus baseline. VAS scores decreased significantly with D-002 (76.6%) and GS/SC (76.8%). The reductions, significant from the second week, were enhanced over the trial. Rescue medications were consumed by 3/30 D-002 and 4/30 GS/SC patients. No differences between groups were found. Treatments were well tolerated.</p<<h4<CONCLUSIONS: D-002 (50 mg/day) administered for 12 weeks was safe and comparable to GS/SC for alleviating OA symptoms (pain, stiffness, and functional limitation) (RPCEC00000180).</h4<</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">D-002, beeswax alcohols, chondroitin sulphate, glucosamine, osteoarthritis, WOMAC score, VAS score</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine (General)</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Roberto Puente</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">José Illnait</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Rosa Mas</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ernesto López</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Daisy Carbajal</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Lilia Fernández</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Julio Fernández</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Meilis Mesa</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Pablo Reyes</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Dalmer Ruiz</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Revista de la Facultad de Ciencias Médicas de Córdoba</subfield><subfield code="d">Universidad Nacional de Córdoba, 2019</subfield><subfield code="g">74(2017), 2, Seite 107-118</subfield><subfield code="w">(DE-627)688608272</subfield><subfield code="w">(DE-600)2654370-9</subfield><subfield code="x">18530605</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:74</subfield><subfield code="g">year:2017</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:107-118</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.31053/1853.0605.v74.n2.14479</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/9f4af7772b29417499bba08598098ab2</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://revistas.unc.edu.ar/index.php/med/article/view/14479</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/0014-6722</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1853-0605</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">74</subfield><subfield code="j">2017</subfield><subfield code="e">2</subfield><subfield code="h">107-118</subfield></datafield></record></collection>
score	7.399583

Nicht das Richtige dabei?

Schreiben Sie uns!

Comparison of the efficacy and tolerability of chondroitin plus glucosamine and D-002 (beeswax alcohols) in subjects with osteoarthritis symptoms

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?